2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Leukemia, Myeloid, Acute
2
Congenital Abnormalities
2
Brain Neoplasms
2
Wilms Tumor
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sezary Syndrome
1
Recurrence
1
Radiation Injuries
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Osteosarcoma
1
Neutropenia
1
Neurotoxicity Syndromes
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Myeloproliferative Disorders
1
Mycosis Fungoides
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Neutrophilic, Chronic
1
Interventions
Rituximab
344
Cyclophosphamide
317
fludarabine phosphate
142
Etoposide
139
Peripheral Blood Stem Cell Transplantation
124
fludarabine
112
Filgrastim
112
Mycophenolic Acid
98
Melphalan
98
Whole-Body Irradiation
90
Vincristine
90
Busulfan
87
Cytarabine
85
Doxorubicin
79
Cyclosporine
76
Tacrolimus
75
Radiotherapy
75
Prednisone
73
Bendamustine Hydrochloride
72
Granulocyte Colony-Stimulating Factor
66
Methotrexate
65
Antilymphocyte Serum
56
Carmustine
54
Dexamethasone
50
Gemcitabine
48
Lenalidomide
46
Bortezomib
43
venetoclax
41
ibritumomab tiuxetan
37
obinutuzumab
36
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Non-Hodgkin
×
Lithium Carbonate
×
Clear all
NCT00408681
2017-03-07
GVHD
Fred Hutchinson Cancer Center
Phase NA
Completed
20 enrolled
27 charts